Clinical characteristics and outcomes in hypertensive patients of hispanic descent

Preventive Cardiology

Volumn 11, Issue 2, 2008, Pages 116-120

  Aranda Jr , Juan M ^a   Calderon, Rafael ^b   Aranda Sr , Juan M ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; ETHNIC DIFFERENCE; HEART INFARCTION; HISPANIC; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MONOTHERAPY; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION; ETHNOLOGY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; HISPANIC AMERICANS; HUMANS; HYPERTENSION; PREVALENCE; TREATMENT OUTCOME;

EID: 45149113145     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.08008.x     Document Type: Review

References (38)

1. Guzmán B. The Hispanic population: Census 2000 brief. Washington, DC: US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2001.
2. US Census Bureau. Current population survey, annual social and economic supplement, 2004. Available at: http://www.census.gov/population/socdemo/ hispanic/ASEC2004/2004CPS_tab1.1a.html. Accessed on June 18, 2007.
3. Ferdinand KC. Hypertension in minority populations. J Clin Hypertens (Greenwich). 2006; 8: 365-368.
4. American Heart Association. Heart Disease and Stroke Statistics - 2007 Update At-a-Glance. Dallas, TX: American Heart Association; 2007.
5. Qureshi AI, Suri MFK, Kirmani JF, et al. Prevalence and trends of prehypertension and hypertension in United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit. 2005; 11: CR403-CR409.
6. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206.
7. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49: 69-75.
8. Centers for Disease Control and Prevention. Hypertension-related mortality among Hispanic subpopulations: United States, 1995-2002. MMWR Morb Mortal Wkly Rep. 2006; 55: 177-180.
9. The Office of Minority Health. Diabetes and Hispanic Americans. http://www.omhrc.gov/templates/content.aspx?ID=3324 Accessed on May 24, 2007.
10. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003; 290: 1884-1890.
11. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992; 19: 403-418.
12. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996; 125: 304-310.
13. Benabe JE, Rios EV. Kidney disease in the Hispanic population: Facing the growing challenge. J Natl Med Assoc. 2004; 96: 789-798.
14. Sorof JM, Lai D, Turner J, et al. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics. 2004; 113: 475-482.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002; 287: 356-359.
16. Wong ND, Lopez V, Tang S, et al. Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States. Am J Cardiol. 2006; 98: 204-208.
17. Giles T, Aranda JM Jr, Suh DC, et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens (Greenwich). 2007; 9: 345-354.
18. Henderson SO, Bretsky P, DeQuattro V, et al. Treatment of hypertension in African Americans and Latinos: The effect of JNC VI on urban prescribing practices. J Clin Hypertens (Greenwich). 2003; 5: 107-112.
19. Hicks LS, Fairchild DG, Horng MS, et al. Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension. 2004; 44: 429-434.
20. Aranda JM Jr, Vazquez R. Awareness of hypertension and diabetes in the Hispanic community. Clin Cornerstone. 2004; 6: 7-15.
21. He J, Muntner P, Chen J, et al. Factors associated with hypertension control in the general population of the United States. Arch Intern Med. 2002; 162: 1051-1058.
22. Kramer H, Han C, Post W, et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2004; 17: 963-970.
23. Soto-Greene ML, Salas-Lopez D, Sanchez J, et al. Antecedents to effective treatment of hypertension in Hispanic populations. Clin Cornerstone. 2004; 6: 30-36.
24. Perez-Stable EJ, Salazar R. Issues in achieving compliance with antihypertensive treatment in the Latino population. Clin Cornerstone. 2004; 6: 49-61.
25. Lai LL. Community pharmacy-based hypertension disease management program in a Latino/Hispanic-American population. Consult Pharm. 2007; 22: 411-416.
26. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-1252.
27. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension. 1998; 31: 1088-1096.
28. Ofili EO, Ferdinand KC, Saunders E, et al; INCLUSIVE Investigators. Irbesartan/HCTZ fixed combinations in patients of different racial/ ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006; 98: 618-626.
29. Ridker PM, Danielson E, Rifai N, et al; Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: Primary report of the Val-MARC trial. Hypertension. 2006; 48: 73-79.
30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
31. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al; INVEST Investigators. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: Findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006; 151: 1072-1079.
32. Yusuf S, Gerstein H, Hoogwerf B, et al; HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001; 286: 1882-1885.
33. Lindholm LH, Ibsen H, Borch-Jahnsen K, et al; LIFE study group. Risk of new-onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens. 2002; 20: 1879-1886.
34. Niklason A, Hedner T, Niskanen L, et al; Captopril Prevention Project Study Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients-a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens. 2004; 22: 645-652.
35. Kjeldsen SE, Julius S, Mancia G, et al; VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J Hypertens. 2006; 24: 1405-1412.
36. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005; 23: 463-473.
37. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
38. Eijkelkamp WB, Zhang Z, Remuzzi G, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007; 18: 1540-1546.